Global Information
회사소개 | 문의 | 비교리스트

신장 섬유증 : 파이프라인 리뷰

Kidney Fibrosis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251573
페이지 정보 영문 174 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신장 섬유증 : 파이프라인 리뷰 Kidney Fibrosis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 174 Pages

신장내에 세포외 기질이 축적되면 신장 섬유증을 일으킵니다. 신장 섬유증은 사구체 경화증과 요세관 간질성 섬유증이 특징인 진행성 질환으로, 신장 기능에 유해 작용을 미치기도 합니다. 소인은 외상, 감염증, 수술, 환경요인과 화학물질 및 방사선 피폭을 들 수 있습니다. 증상은 통증, 배뇨 관련 문제, 구역과 구토 등이 있습니다. 약물 및 신장이식으로 증상을 관리합니다.

신장 섬유증 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

신장 섬유증 개요

치료제 개발

  • 파이프라인 제품;개요
  • 파이프라인 제품;기업별
  • 파이프라인 제품;대학/기관별
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • AbbVie Inc
  • Allergan Plc
  • Angion Biomedica Corp
  • Apollo Endosurgery Inc
  • BiOrion Technologies BV
  • Cellmid Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Horizon Pharma Plc
  • Intercept Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • MorphoSys AG
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Regulus Therapeutics Inc
  • Sirnaomics Inc
  • Symic Biomedical Inc
  • Vascular Biogenics Ltd

약제 개요

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.11.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Kidney Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Kidney Fibrosis - Pipeline by AdAlta Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2020
  • Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2020
  • Kidney Fibrosis - Pipeline by Blade Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Curacle Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Evotec SE, H1 2020
  • Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Galapagos NV, H1 2020
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2020
  • Kidney Fibrosis - Pipeline by iBio Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2020
  • Kidney Fibrosis - Pipeline by Kadmon Corp LLC, H1 2020
  • Kidney Fibrosis - Pipeline by Liminal BioSciences Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Max Biopharma Inc, H1 2020
  • Kidney Fibrosis - Pipeline by MedPacto Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by NB Health Laboratory Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Novo Nordisk AS, H1 2020
  • Kidney Fibrosis - Pipeline by Oasis Pharmaceuticals LLC, H1 2020
  • Kidney Fibrosis - Pipeline by Osteoneurogen Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Redx Pharma Plc, H1 2020
  • Kidney Fibrosis - Pipeline by Sanofi, H1 2020
  • Kidney Fibrosis - Pipeline by Scholar Rock Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Senolytic Therapeutics Inc, H1 2020
  • Kidney Fibrosis - Pipeline by TiumBio Co Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2020
  • Kidney Fibrosis - Pipeline by Transcenta Holding Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2020
  • Kidney Fibrosis - Pipeline by Vectus Biosystems Ltd, H1 2020
  • Kidney Fibrosis - Dormant Projects, H1 2020
  • Kidney Fibrosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Kidney Fibrosis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Kidney Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 34 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Kidney Fibrosis - Overview
  • Kidney Fibrosis - Therapeutics Development
  • Kidney Fibrosis - Therapeutics Assessment
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
  • Kidney Fibrosis - Drug Profiles
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Discontinued Products
  • Kidney Fibrosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q